Τίτλος:
The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: To evaluate the characteristics of corneal parameters in patients with diabetic macular oedema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: Participants in this study were 36 patients with DME, treated with either intravitreal ranibizumab (n = 16) or aflibercept (n = 20). All participants underwent best-corrected visual acuity (BCVA) measurement, optical coherence tomography and non-contact specular microscopy to evaluate corneal endothelium parameters (endothelial cell density-ECD, hexagonality, coefficient of variation of the cell size and central corneal thickness-CCT), at baseline and at months 6 and 12 after the first intravitreal injection. Comparisons between baseline and months 6 and 12 were performed. Results: There was no statistically significant difference regarding ECD, hexagonality, coefficient of variation of the cell size and CCT at month 6 and 12 post initial injection compared to baseline in patients with DME. BCVA improved significantly at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Central retinal thickness was significantly reduced at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Conclusion: Intravitreal anti-VEGF injections in patients with DME were found not to affect corneal parameters, namely ECD, hexagonality, coefficient of variation of the cell size and CCT at the long-term follow-up of 12 months. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Chatziralli, I.
Papadakou, P.
Dimitriou, E.
Kazantzis, D.
Kapsis, P.
Theodossiadis, G.
Papathanassiou, M.
Theodossiadis, P.
Περιοδικό:
Cutaneous and Ocular Toxicology (formerly Journal of Toxicology - Cutaneous and Ocular Toxicology)
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
aflibercept; hemoglobin A1c; ranibizumab; aflibercept; angiogenesis inhibitor; fusion protein; ranibizumab; vasculotropin; vasculotropin receptor, adult; Article; best corrected visual acuity; cell density; cell size; central corneal thickness; central retinal thickness; clinical article; comorbidity; controlled study; cornea endothelium; diabetic macular edema; engineering; female; fluorescence angiography; follow up; human; intraocular pressure; loading drug dose; male; middle aged; optical coherence tomography; prospective study; slit lamp microscopy; spectral domain optical coherence tomography; specular microscopy; aged; clinical trial; cornea endothelium; diabetic complication; drug effect; intravitreal drug administration; macular edema; visual acuity, Aged; Angiogenesis Inhibitors; Diabetes Complications; Endothelium, Corneal; Female; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Vascular Endothelial Growth Factors; Visual Acuity
DOI:
10.1080/15569527.2021.1887886
